Evidence map›Paper›PMID 34677688›Full record

ArticleJournal, genetic engineering & biotechnology2021

The potential role of inhaled nitric oxide for postexposure chemoprophylaxis of COVID-19.

Antoine AbdelMassih, Rafeef Hozaien, Meryam El Shershaby, Aya Kamel, Habiba-Allah Ismail, Mariem Arsanyous, Nadine El-Husseiny, Noha Khalil, Youstina Naeem, Raghda Fouda

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal, genetic engineering & biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Antoine AbdelMassihPediatric Cardiology unit, Pediatrics' Department, Faculty of Medicine, Cairo University, Cairo, Egypt. antoine.abdelmassih@kasralainy.edu.eg.ORCID http://orcid.org/0000-0001-8876-3229
Rafeef HozaienResearch Accessibility Team, Student and Internship research program Faculty of Medicine, Cairo University, Cairo, Egypt.
Meryam El ShershabyResearch Accessibility Team, Student and Internship research program Faculty of Medicine, Cairo University, Cairo, Egypt.
Aya KamelResearch Accessibility Team, Student and Internship research program Faculty of Medicine, Cairo University, Cairo, Egypt.
Habiba-Allah IsmailResearch Accessibility Team, Student and Internship research program Faculty of Medicine, Cairo University, Cairo, Egypt.
Mariem ArsanyousResearch Accessibility Team, Student and Internship research program Faculty of Medicine, Cairo University, Cairo, Egypt.
Nadine El-HusseinyFaculty of Dentistry, Cairo University, Cairo, Egypt.
Noha KhalilResearch Accessibility Team, Student and Internship research program Faculty of Medicine, Cairo University, Cairo, Egypt.
Youstina NaeemResearch Accessibility Team, Student and Internship research program Faculty of Medicine, Cairo University, Cairo, Egypt.
Raghda FoudaClinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Cairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeveral vaccines have been fast-tracked in an attempt to decrease the morbidity and mortality of COVID-19. However, post-exposure prophylaxis has been overlooked in battling COVID-19. MAIN TEXT: Inhaled nitric oxide is a potential tool in post-exposure prophylaxis of COVID-19. It decreases cytosolic calcium levels, which impairs the action of Furin. SARS-CoV-2 uses Furin to replicate in the respiratory tract. SHORT

conclusionInhaled nitric oxide could decrease the viral load in the upper respiratory tract, abort clinically symptomatic infection, and prevent subsequent complications. Nitric oxide might be a tool for post-exposure chemoprophylaxis in at-risk groups, especially medical personnel.

Identifiers

PMID34677688
PMCPMC8532099
OpenAlexW3205839399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.